In last trading session, the stock price of Pharmacyte Biotech Inc (OTCMKTS:PMCB) declined 0.52% to close the week at $0.0959. The decline came at a share volume of 1.06 million compared to monthly average share volume of 1.52 million. Pharmacyte stock has been stuck in a low trading session from last few trading sessions.
Recently, the company’s CEO Mr. Kenneth L. Waggoner, JD interview got published in PharmaVOICE wherein it stated that company will take expert advice of the three known physicians in oncology. The team of three experts will guide them in advancing planned clinical studies to treat advanced pancreatic cancer and further contribute in the planning of future studies.
Uluru Inc (OTCMKTS:ULUR) Updates On Quarterly Performance
Uluru Inc (OTCMKTS:ULUR) reported a net loss of $729,000 in the second quarter of fiscal versus a net loss of $710,000 in the comparable period in 2014. For the first six months completed June 30, the net loss amounted to $1.47 million versus a net loss of $1.58 million in 2Q2014.
In the reported quarter, the company reported positive interim report of the pharmaco-economic assessment process being done in Europe. Also, Uluru obtained marketing consent in Russia to kick off sales of Altrazeal®. In 2Q2015, the company successfully closed the first order of Altrazeal® for Egypt and partially completed the order of Saudi Arabia. Kerry P. Gray, the CEO stated that company’s geographic expansion is moving as planned and with more approvals, they anticipate increased product launches in various regions including Europe and Russia.
In last trading session, the stock price of ULUR jumped more than 3% to close the week at $0.340.
DARA Biosciences Inc (NASDAQ:DARA) Trades In Narrow Range
In last trading session, the stock price of DARA Biosciences Inc (NASDAQ:DARA) gained 0.98% and closed at $0.823. The Pharma company disclosed that it will be participate in the “Rodman and Renshaw Global Investment Conference” to be held this week.